Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 311 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment-Resistant Depression Clear all
Completed Phase 2 Interventional

A Study of RO4917523 in Patients With Treatment Resistant Depression

NCT00809562
View directory record Official record
Conditions
Depression
Interventions
Placebo, RO4917523
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Oceanside, California • San Diego, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

NCT02134808
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Creatine, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Phase 2 Interventional

Mindfulness Engaged Neurostimulation for Depression (MEND II)

NCT07512284
View directory record Official record
Conditions
Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder, Depressive Symptoms
Interventions
Medi-TBS
Combination Product
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 4, 2026, 7:05 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

PET Biomarkers in Treatment Resistant Depression

NCT01031810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Not applicable Interventional

The RAFT ECT Study

NCT05402657
View directory record Official record
Conditions
Major Depressive Episode
Interventions
Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
Procedure
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed No phase listed Observational

Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI

NCT05598931
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Transcranial Magnetic Stimulation
Device
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Not applicable Interventional

Implementation Trial of Evidence Based Practices for Mood Disorders

NCT02150577
View directory record Official record
Conditions
Bipolar Disorder, Treatment Resistant Depression
Interventions
Evidence Based Quality Improvement
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 100 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Eudora, Arkansas • Huntsville, Arkansas • Marianna, Arkansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 4, 2026, 7:05 PM EDT
Suspended Not applicable Interventional

Enhanced Spatial Targeting in ECT Utilizing FEAST

NCT04099342
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
FEAST, FEAST RP
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Phase 1 Interventional

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

NCT03973268
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Major Depression
Interventions
Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions
Device · Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Not applicable Interventional Results available

Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression

NCT03953417
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Accelerated intermittent theta-burst treatment
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01309945
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Placebo matching with BMS-820836, BMS-820836, Placebo matching with Duloxetine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Little Rock, Arkansas • Arcadia, California • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 4, 2026, 7:05 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583
View directory record Official record
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Not applicable Interventional

PCS in Severe Treatment Resistant Depression

NCT04124341
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Prefrontal Cortical Stimulation (PCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Not applicable Interventional Results available

Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression

NCT00186485
View directory record Official record
Conditions
Bipolar Disorder
Interventions
MagStim
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 4 Interventional Results available

Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression

NCT00608543
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Phase 4 Interventional

Establishing Mobile Transcranial Magnetic Stimulation

NCT06748209
View directory record Official record
Conditions
Treatment Resistant Major Depression
Interventions
Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 2 Interventional

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

NCT01234558
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
GLYX-13
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Not applicable Interventional Results available

Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms

NCT02611206
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS): intensity 80% MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 100% of MT, Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Stimulation intesity: 120% of MT
Device
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 4, 2026, 7:05 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Not applicable Interventional

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

NCT03887715
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Vagus Nerve Stimulation (VNS)
Device
Lead sponsor
LivaNova
Industry
Eligibility
18 Years and older
Enrollment
6,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
101
States / cities
Birmingham, Alabama • Huntsville, Alabama • Burlingame, California + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 4, 2026, 7:05 PM EDT
Recruiting Not applicable Interventional

Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression

NCT03952962
View directory record Official record
Conditions
Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
Interventions
Abbott Laboratories Infinity™ implantable deep brain stimulation system
Device
Lead sponsor
Nader Pouratian
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 4, 2026, 7:05 PM EDT